Anupam Rasayan India Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹806 Cr +10.3% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
AR

Anupam Rasayan India Ltd

Q4 FY26Chemicals & Petrochemicals

Anupam Rasayan India Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹636Cr
+27.2% YoY
+24.2% QoQ
Net profit
₹56Cr
−11.1% YoY
−8.2% QoQ
Margin
22%
−7 pp YoY
−3 pp QoQ
Price₹1,244
Market cap₹13.8K Cr
P/E81.4

The short version

Stand-alone business expects 20%-30% CAGR growth over the next 3-5 years, recovering past losses and expanding across agro, pharma, and polymer verticals. Anupam Rasayan expects a 20-30% CAGR growth over the next 3-5 years in standalone business revenues, driven primarily by Pharma and Polymer segments.

From Anupam Rasayan India Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Stand-alone business expects 20%-30% CAGR growth over the next 3-5 years, recovering past losses and expanding across agro, pharma, and polymer verticals.
  • Order book at INR14,000 crores indicates potential INR1,700-1,800 crores additional incremental annual revenue mainly from agro and polymer segments.
  • Pharma segment contribution has grown from near 0% to 20%, expected to continue strong organic growth domestically.
  • Acquisitions of Bliss and Jayhawk add further growth from new customers and geographies including US, Europe, and India.
  • Bliss currently operates at ~30% capacity utilization, expected to ramp to 60%-70% driving revenue growth.

2 more points from Anupam Rasayan India Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Anupam Rasayan India Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

- Ongoing INR250 crores capex at Halol facility is for the CDMO business tied to a major multinational pharma client; it is separate from other plant capex and has a longer gestation period with expected 4x-5x asset turnover. - Stand-alone operations at Anupam have no major incremental capex planned; maintenance capex expected around INR50-75 crores annually over next 2-3 years. - Last year, Anupam completed a capex program with INR315 crores spent; all plants now commercialized. - No major near-term capex is envisaged for current capacity which sufficiently supports near-term growth. Overall, focus is on utilizing existing capacities, targeted maintenance capex, and select strategic capex like Halol for CDMO expansion.

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Anupam Rasayan India Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Current order book stands at around INR 14,000 crores.
  • On a 6 to 7-year average, the company anticipates adding INR 2,200 crores in incremental annual revenue from the existing pipeline.
  • Of this incremental revenue, INR 1,700-1,800 crores is expected to come from agro and polymer segments.
  • Additional new projects in the polymer business are expected to drive further growth.
  • The pharma segment is also continuously growing organically, primarily from the Indian market.

2 more points from Anupam Rasayan India Ltd's call on order book

Create a free account to keep reading this call

Anupam Rasayan India Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Anupam Rasayan India Ltd Q4 FY26 results — key figures

Anupam Rasayan India Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue636500+27.2%512+24.2%
Operating profit (EBITDA)137144-4.9%127+7.9%
Operating margin22%29%-7 pp25%-3 pp
Profit before tax5688-36.4%60-6.7%
Net profit (PAT)5663-11.1%61-8.2%
EPS (₹)3.754.05-7.4%4.31-13%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹806 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Indian Phosphate (Q4 FY26)

    H2 FY26 Revenue (Consolidated):** ₹580.25 Cr, up from ₹451.59 Cr in H2 FY25 — a year-on-year increase of ₹128.66 Cr. Key investor presentation takeaways from In

  • Paragon Fine (Q4 FY26)

    Revenue for H2FY26:** Rs 68.88 Cr, up 7.41% YoY from Rs 64.13 Cr in H2FY25 (Page 22). Key investor presentation takeaways from Paragon Fine's Q4 FY26 investor p

  • IVP (Q4 FY26)

    Q4 FY26 revenue from operations: ₹164.44 crore . Key investor presentation takeaways from IVP's Q4 FY26 investor presentation — and how it ranks against sector

  • Vishnu Chemicals (Q4 FY26)

    Q4 FY26 Operating Revenues: ₹450.3 crore, up 14.7% YoY from ₹392.6 crore in Q4 FY25 (Page 5). Key investor presentation takeaways from Vishnu Chemicals Ltd's Q4

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Anupam Rasayan India Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Anupam Rasayan India Ltd Q4 FY26 results?

Stand-alone business expects 20%-30% CAGR growth over the next 3-5 years, recovering past losses and expanding across agro, pharma, and polymer verticals. Anupam Rasayan expects a 20-30% CAGR growth over the next 3-5 years in standalone business revenues, driven primarily by Pharma and Polymer segments.

What is Anupam Rasayan India Ltd share price analysis?

Anupam Rasayan India Ltd currently shows a neutral. The stock trades at a P/E of 81.4 with a market cap of ₹13,847 Cr. Investors should review the full earnings analysis for detailed insights.

Is Anupam Rasayan India Ltd planning capital expenditure?

Ongoing INR250 crores capex at Halol facility is for the CDMO business tied to a major multinational pharma client; it is separate from other plant capex and has a longer gestation period with expected 4x-5x asset turnover.

Keep Anupam Rasayan India Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.